Bausch Health shares jump 10% after first-quarter revenue beat

9 articles · Updated · MarketWatch · Apr 30

The Laval, Quebec, drugmaker posted revenue of $2.52 billion, up from $2.26 billion and above analysts' $2.41 billion forecast, while adjusted earnings reached 78 cents a share.
Growth was led by an 18% rise in Salix and a 51% surge at Solta Medical after its China aesthetics acquisition; the international unit rose 9%, while diversified revenue fell 10%.
Bausch reported a $1.42 billion quarterly loss, widened by a Salix RED-C impairment charge, but reaffirmed full-year revenue guidance of $10.67 billion to $10.92 billion and EBITDA guidance of $3.89 billion to $4.01 billion.

Can surging aesthetic sales rescue Bausch Health before its blockbuster drug's patent expires in 2028?

With its Bausch + Lomb stake worth double its market cap, is Bausch Health a hidden gem or a classic value trap?